[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aids-related-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aids-related-lymphoma":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100648856","optimization-of-antiretroviral-therapy-in-patients-with-aids-related-lymphoma-100648856",false,"NCT07727642","Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma","Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma During Anti-Lymphoma Treatment: A Multicenter Prospective Non-Randomized Controlled Study","OPT-ARL","Inclusion Criteria:\n\n\\- Age ≥18 years. Confirmed HIV infection. Histologically confirmed AIDS-related lymphoma. Receiving anti-lymphoma treatment. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n\\- Expected survival less than 6 months. Severe concomitant malignancy or uncontrolled comorbidity. Refusal to receive antiretroviral therapy or lymphoma treatment. Contraindications to study medications. Inability to complete scheduled follow-up. Any condition considered unsuitable by the investigator.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strategies in adults with AIDS-related lymphoma (ARL) receiving anti-lymphoma treatment. The main questions it aims to answer are:\n\nDoes long-acting injectable ART, including albuvirtide (ABT) or long-acting cabotegravir\u002Frilpivirine (CAB\u002FRPV), improve virological suppression compared with oral ART during anti-lymphoma treatment? Do different ART strategies differ in immune recovery, virological failure, low-level viremia, and safety in patients with ARL?\n\nResearchers will compare three treatment strategies-oral ART alone, oral ART plus long-acting albuvirtide (ABT), and long-acting cabotegravir\u002Frilpivirine (CAB\u002FRPV)-to determine whether long-acting injectable ART provides better virological control and comparable safety during lymphoma treatment.\n\nParticipants will:\n\nReceive one of three ART strategies according to their clinical condition and treatment preference while receiving standard anti-lymphoma therapy.\n\nAttend scheduled study visits at baseline and Weeks 4, 8, 12, 24, 36, and 48. Undergo plasma HIV-1 RNA testing, CD4+ T-cell count measurement, laboratory assessments, and safety evaluations throughout the 48-week follow-up period.\n\nBe monitored for virological suppression, immune recovery, adverse events, and lymphoma-related clinical outcomes.",[27,28],"AIDS-related Lymphoma","HIV Infection",[30,31,32,33,34,35,36,37],"HIV","AIDS-Related Lymphoma","Antiretroviral Therapy","Albuvirtide","Cabotegravir","Rilpivirine","Long-Acting Injectable ART","Virological Suppression","RECRUITING","2026-07-22",{"date":41,"type":42},"2026-07-27","ACTUAL",{"date":44,"type":42},"2026-05-26",{"date":46,"type":21},"2028-07",{"name":48,"class":49},"Shanghai Public Health Clinical Center","OTHER_GOV",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100457018","a-registry-study-on-hiv-related-lymphoma-100457018","NCT05231135","A Registry Study on HIV-related Lymphoma","Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group","Inclusion Criteria:\n\n* Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma\n* HIV-infection at time of lymphoma diagnosis\n* Lymphoma diagnosis since 01.01.2010\n* Adult patients ≥ 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* HIV-diagnosis \\> 3 months after the diagnosis of malignant lymphoma\n* Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)",{"count":59,"type":21},300,"6 Years","OBSERVATIONAL","Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.",[64,65],"AIDS Related Lymphoma","HIV Related Lymphoma",[67,68,69],"Malignant lymphoma","HIV-related lymphoma","HIV-associated Hodgkin lymphoma","2023-04-04",{"date":72,"type":42},"2023-04-06",{"date":74,"type":42},"2021-08-25",{"date":76,"type":21},"2029-08-31",{"name":78,"class":79},"Rotkreuzklinikum München gGmbH","OTHER",6]